CTOs on the Move

Inscripta, Inc

www.inscripta.com

 
Inscripta is a gene-editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Inscripta, Inc raised $55.5M on 02/28/2018
Inscripta, Inc raised $30M on 12/18/2018
Inscripta, Inc raised $20M on 04/04/2019

Similar Companies

Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio`s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world`s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.

Freeline

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We are headquartered in the UK and we also have operations in Germany and the US. Freeline was founded in 2015 and builds upon the pioneering work by our Clinical and Scientific Advisor and Director, Professor Amit Nathwani, Professor of Haematology at UCL. With our liver-based investigational gene therapy technology, we aim to improve the lives of people with chronic systemic diseases and realise the potential of gene therapy treatments.

Taysha Gene Therapies

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we hope to rapidly translate our treatments from bench to bedside. We have combined our team`s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for new cures—to dramatically improve patients` lives.

Kira Pharmaceuticals

Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases

Ecovative Design

Ecovative uses biology to solve fundamental human needs at industrial scales and in consumer applications. Ecovative uses mycelium to grow category defining products ranging from leather like textiles to sustainable packaging to high performance foams for apparel and beauty.